News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Analyst fair value for Boston Scientific has shifted from US$75.00 to US$72.25, pointing to a modest reset in price targets. This change lines up with recent research …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%Boston Scientific exceeded Q2 2026 earnings and revenue forecasts but saw its stock fall due to a lowered full-year outlook and concerns about its WATCHMAN and electrophysiology businesses. The company reported adjusted EPS of $0.86 and revenue of $5.44 billion, topping analyst estimates. Management …
This article provides a brief snapshot of Boston Scientific's (BSX) Q2 earnings. No specific financial details are available in the provided content, as the article appears to be a placeholder or an incomplete data capture.
Boston Scientific has faced competitive pressure in its key growth areas, despite a strong history of innovation and operational efficiency. Under CEO Michael Mahoney, the company has focused on novel technology and accelerating growth. The article suggests that competitive forces are impacting the medical …
Boston Scientific recently reported its second-quarter 2026 results, showing sales of US$5,442 million and net income of US$907 million, alongside issuing a recall of its Rapid Refill Continuous Injection System and initiating a multi-year global restructuring plan aimed at cost efficiencies. While the company …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%Boston Scientific Corporation Q2 2026 Earnings Call Summary - Moby Performance Attribution and Strategic Context Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …
Boston Scientific has cut its 2026 sales and earnings per share guidance for the second consecutive quarter, citing struggles in its electrophysiology and Watchman businesses. CEO Mike Mahoney stated that market conditions have evolved quickly, making forecasting challenging, and the company expects Watchman growth …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%This article first appeared on GuruFocus. Organic Sales Growth: 7% in Q2 2026, driven by Interventional Cardiology, Endoscopy, and Neuromodulation. Adjusted EPS: $0.86, a 15% increase, exceeding guidance range of $0.82 to $0.84. Adjusted Operating Margin: 28.4% in Q2 2026. Full Year 2026 Organic …
Boston Scientific Corp. (Nasdaq: BSX) is reducing its 2026 revenue outlook for the second time, lowering it to 5%-6% from an initial 10%-11%. This comes as the company faces challenges with key revenue drivers. In response, Boston Scientific plans to cut jobs in Houston …
Boston Scientific beats second quarter expectations, raises full-year outlook Proactive uses images sourced from Shutterstock Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst expectations for revenue and adjusted earnings, while raising its full-year sales outlook. The medical device company posted …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%Boston Scientific has lowered its revenue outlook, citing rapidly evolving market conditions and increased competition in its cardiovascular business, particularly in pulsed field ablation and heart devices. CEO Michael F. Mahoney acknowledged the challenge in forecasting effectively. The company is implementing a restructuring plan …
Boston Scientific has reported Q2 revenues of around $5.4bn, indicative of a 7.5% year-over-year (YoY) rise, yet has elected to trim its full-year outlook. The lion's share of Boston's revenues came from its cardiovascular segment at around $3.6bn, indicative of an 8.3% YoY uplift …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%Boston Scientific (NYSE: BSX) has cut its fiscal 2026 outlook due to a slowdown in the U.S. Watchman heart implant market and increased competition in the EP market, causing its stock to trade lower. Despite beating Q2 revenue and adjusted earnings estimates, the company …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%For the quarter ended June 2026, Boston Scientific (BSX) reported revenue of $5.44 billion, up 7.5% over the same period last year. EPS came in at $0.86, compared to $0.75 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%Boston Scientific lowered its full-year sales outlook due to unexpected challenges with two core heart-disease products. The company's Watchman heart implant experienced a sharp and unexpected slowdown in revenue, and its electrophysiology business is struggling against increased competition. This adjustment follows the release of …
Medical device manufacturer Boston Scientific has informed the Irish Government of potential job cuts at its Irish operations, following the approval of a global restructuring plan aimed at cutting costs. The Department of Enterprise received a collective redundancy notification, indicating 30 or more potential …
Boston Scientific (NYSE: BSX) reported solid second-quarter 2026 results, with net sales reaching $5.442 billion, a 7.5% increase year-over-year. The company's GAAP EPS was $0.61, and adjusted EPS hit $0.86, surpassing guidance. Key achievements included strategic investments, advancements in cardiovascular and orthopedic solutions with …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%Boston Scientific (BSX) beat second-quarter earnings expectations but cut its full-year profit forecast due to slower-than-expected demand for its Watchman heart implant. The company now projects adjusted EPS between $3.28 and $3.32, down from its previous guidance. This reduction is attributed to changing clinical …
Boston Scientific (BSX) stock fell by nearly 6% in premarket trading despite reporting better-than-expected Q2 2026 financials. The decline was triggered by the medical device maker setting its Q3 and full-year earnings outlook below analysts’ estimates. The Massachusetts-based company reported $5.4 billion in revenue.
Woman looking through microscope ©The U.S. National Archives Boston Scientific (NYSE:BSX) shares rose more than 3% in pre-market trading on Wednesday after the medical device manufacturer reported second-quarter earnings and revenue that exceeded Wall Street expectations, supported by broad-based growth across its business. The …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%July 29 (Reuters) - Medical device maker Boston Scientific on Wednesday lowered its annual profit forecast, citing pressure on its Watchman heart device business. The company, in May, warned of pressure on its Watchman heart device, a small implant used to help prevent stroke-causing …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%Investing.com -- Shares in Boston Scientific rose over 3% in premarket trading Wednesday after the medical device maker reported second-quarter earnings and revenue that topped Wall Street estimates. The company posted second-quarter earnings per share of $0.86, beating the analyst estimate of $0.83. Revenue …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%Boston Scientific (NYSE:BSX) Surprises With Q2 CY2026 Sales But Quarterly Revenue Guidance Misses Expectations Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 7.5% year on year to $5.44 billion. On the other hand, …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%(RTTNews) - Boston Scientific Corp (BSX) will host a conference call at 8:00 AM ET on July 29, 2026, to discuss Q2 26 earnings results. To access the live webcast, log on to https://investors.bostonscientific.com/events-and-presentations The views and opinions expressed herein are the views and …
Sharemaestro market context Price below Trend Line 52 weeks -55.4% · Next-week setup negative 44.4%The Federal Circuit has reversed a patent victory obtained by the University of Texas against Boston Scientific. This decision impacts a legal dispute concerning patent infringement.
Boston Scientific is implementing a global restructuring plan that will result in job cuts. The medical device company's decision was announced as part of an effort to streamline operations and adapt to changing market conditions. Details regarding the number of affected employees and specific …
Boston Scientific Corp. (BSX) stock rose 1.21% on Tuesday, closing at $46.06. Despite this gain, the stock underperformed compared to the broader market, as the S&P 500 Index and Dow Jones Industrial Average both saw larger increases. This marks the fourth consecutive day of …
Boston Scientific has approved a major restructuring plan to reduce annual costs by approximately $500 million by 2029. This initiative, which will cost between $700 million and $800 million and include job eliminations, is aimed at re-investing savings into strategic growth areas. The restructuring …
UBS has lowered its price target for Boston Scientific (NYSE:BSX) to $74 from $95 but maintained a Buy rating, citing that shares are near five-year lows without a structural change in business fundamentals. The firm believes the market has overly focused on key revenue …
Boston Scientific is set to report second-quarter earnings with investors keenly focused on the performance of its WATCHMAN device, which has seen slowed sales, and the company's full-year guidance. Analysts expect modest EPS and revenue growth, but the stock has fallen significantly, and some …
Search by ticker symbol or company name and select a result to open its chart.